Loss to follow-up occurs at all stages in the diagnostic and follow-up period among HIV-infected patients in Guinea-Bissau: A 7-year retrospective cohort study

BMJ Open

Volumn 3, Issue 10, 2013, Pages

  Hønge, Bo Langhoff ^a,b   Jespersen, Sanne ^a,b   Nordentoft, Pernille Bejer ^a,b   Medina, Candida ^c   Da Silva, David ^c   Da Silva, Zacarias José ^a,d   Østergaard, Lars ^b   Laursen, Alex Lund ^b   Wejse, Christian ^a,b,e  

^a Studies of the Epidemiology of Epilepsy in Demographic Surveillance Systems   (Guinea-Bissau)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c Ministry of Health   (Guinea-Bissau)

^d National Public Health Laboratory   (Guinea-Bissau)

^e GloHAU   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; FEMALE; FOLLOW UP; GUINEA-BISSAU; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE;

EID: 84886671992     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-003499     Document Type: Article

References (42)

1. UNAIDS Data Tables 2011. http://www.unaids.org/en/media/unaids/ contentassets/documents/unaidspublication/2011/JC2225-UNAIDS-datatables-en.pdf (accessed 4 Jun 2013).
2. May M, Sterne JA, Sabin C, et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007;21:1185-97. (Pubitemid 46763289)
3. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS ONE 2009;4:e5790.
4. Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 2007;21:965-71. (Pubitemid 46684328)
5. Adje C, Cheingsong R, Roels TH, et al. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr 2001;26:501-6. (Pubitemid 32489032)
6. Mugusi F, Mugusi S, Bakari M, et al. Enhancing adherence to antiretroviral therapy at the HIV clinic in resource constrained countries; the Tanzanian experience. Trop Med Int Health 2009;14:1226-32.
7. Bartlett JA, Shao JF. Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries. Lancet Infect Dis 2009;9:637-49.
8. Brinkhof MW, Dabis F, Myer L, et al. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower income countries. Bull World Health Organ 2008;86:497-576.
9. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 2007;4:e298.
10. An MW, Frangakis CE, Musick BS, et al. The need for double-sampling designs in survival studies: an application to monitor PEPFAR. Biometrics 2009;65:301-6.
11. Bisson GP, Gaolathe T, Gross R, et al. Overestimates of survival after HAART: implications for global scale-up efforts. PLoS ONE 2008;3:e1725.
12. Ulett KB, Willig JH, Lin HY, et al. The therapeutic implications of timely linkage and early retention in HIV care. AIDS Patient Care STDS 2009;23:41-9.
13. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009;373:1352-63.
14. Larson BA, Brennan A, McNamara L, et al. Early loss to follow-up after enrolment in pre-ART care at a large public clinic in Johannesburg, South Africa. Trop Med Int Health 2010;15:43-7.
15. Amuron B, Nmara G, Birungi J, et al. Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health 2009;9:290.
16. Togun T, Peterson I, Jaffar S, et al. Pre-treatment mortality and loss-to-follow-up in HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients eligible for antiretroviral therapy in the Gambia, West Africa. AIDS Res Ther 2011;8:24.
17. Mugglin C, Estill J, Wandeler G, et al. Loss to programme between HIV diagnosis and initiation of antiretroviral therapy in sub-Saharan Africa: systematic review and meta-analysis. Trop Med Int Health 2012;17:1509-20.
18. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med 2011;8:e1001056.
19. Ochieng-Ooko V, Ochieng D, Sidje JE, et al. Influence of gender on loss to follow-up in a large HIV treatment programme in western Kenya. Bull World Health Organ 2010;88:681-8.
20. Geng EH, Bangsberg DR, Musinguzi N, et al. Understanding the reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr 2010;53:405-11.
21. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource limited settings: systematic review and meta-analysis. PLoS ONE 2009;4:e5790.
22. Chaillet P, Tayler-Smith K, Zachariah R, et al. Evaluation of four rapid tests for diagnosis and differentiation of HIV-1 and HIV-2 infections in Guinea-Conakry, West Africa. Trans R Soc Trop Med Hyg 2010;104:571-6.
23. Hønge BL, Bjarnason MPO, Jespersen S, et al. Performance of three rapid tests for discrimination between HIV-1 and HIV-2 in Guinea-Bissau, West Africa. J Acquir Immune Defic Syndr [Epub ahead of print 26 Aug 2013].
24. Chi BH, Yiannoutsos CT, Westfall AO, et al. Universal definition of loss to follow-up in HIV treatment programs: a statistical analysis of 111 facilities in Africa, Asia, and Latin America. PLoS Med 2011;8: e1001111.
25. Chi BH, Cantrell RA, Mwango A, et al. An emperical approach to defining loss to follow-up among patients enrolled in antiretroviral treatment programs. Am J Epidemiol 2010;171:924-31.
26. Erikstrup C, Kallestrup P, Zinyama R, et al. Predictors of mortality in a cohort of HIV-1 infected adults in rural Africa. J Acquir Immune Defic Syndr 2007;44:478-83. (Pubitemid 46555385)
27. Oliviera I, Andersen A, Furtado A, et al. Assessment of simple risk markers for early mortality among HIV-infected patients in Guinea-Bissau: a cohort study. BMJ Open 2012;2:e001587.
28. Nielsen J, Jensen H, Andersen PK, et al. Mortality patterns during a war in Guinea-Bissau 1998-99: changes in risk factors? Int J Epidemiol 2006;35:438-46.
29. Karcher H, Omondi A, Odora J, et al. Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya. Trop Med Int Health 2007;12:687-94. (Pubitemid 46625297)
30. Bygrave H, Mtangirwa J, Ncube K, et al. Antiretroviral therapy outcomes among adolescents an youth in rural Zimbabwe. PLoS ONE 2012;7:e52856.
31. Somi G, Keogh SC, Todd J, et al. Low mortality risk but high loss to follow-up among patients in the Tanzanian national HIV care and treatment programme. Trop Med Int Health 2012;17:497-506.
32. Onoka CA, Uzochukwu BS, Onwujekwe OE, et al. Retention and loss to follow-up in antiretroviral treatment programmes in southeast Nigeria. Pathog Glob Health 2012;106:46-54.
33. Marlink R, Kanki P, Thior I, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994;265:1587-90. (Pubitemid 24308975)
34. Togun T, Peterson I, Jaffar S, et al. Pre-treatment mortality and loss-to-follow-up in HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients eligible for antiretroviral therapy in The Gambia, West Africa. AIDS Res Ther 2011;8:24.
35. Lewden C, Gabillard D, Minga A, et al. CD4-specific mortality rates among HIV-infected adults with high CD4 count and no antiretroviral treatment in West Africa. J Acquir Immune Defic Syndr 2012;59:213-19.
36. Torpey KE, Kabaso ME, Mutale LN, et al. Adherence support workers: a way to address human resource constraints in antiretroviral treatment programs in the public health setting in Zambia. PLoS ONE 2008;3:2204.
37. Lester RT, Ritvo P, Mills EJ, et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomized trial. Lancet2010;376:1838-45.
38. Myer L, el-Sadr W. Expanding access to antiretroviral therapy through the public sector-the challenge of retaining patients in long-term primary care. S Afri Med J 2004;94:273-4. (Pubitemid 38585219)
39. Losina E, Touré H, Uhler LM, et al. Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal. PLoS Med2009;6:e10000173.
40. Geng EH, Hare CB, Kahn JO, et al. The effect of a "Universal Antiretroviral Therapy" recommendation on HIV RNA levels among HIV-infected patients entering care with a CD4 count greater 500/μl in a public health setting. Clin Infect Dis 2012;12:1690-7.
41. Le T, Wright EJ, Smith DM, et al. Enhanced CD4+ T-cell recovery with earlierHIV-1 antiretroviral therapy. N EnglJ Med 2013;368:218-30.
42. da Silva ZJ, Oliveira I, Andersen A, et al. Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: is HIV-2 disappearing? AIDS 2008;22:1195-202.